CD133 antibody-conjugated immunoliposomes encapsulating gemcitabine for targeting glioblastoma stem cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Dae Hwan | - |
dc.contributor.author | Xuan, Shuhua | - |
dc.contributor.author | Kim, Woo-Young | - |
dc.contributor.author | Bae, Gyu-Un | - |
dc.contributor.author | Kim, Jin-Seok | - |
dc.date.available | 2021-02-22T11:48:31Z | - |
dc.date.issued | 2014-06 | - |
dc.identifier.issn | 2050-7518 | - |
dc.identifier.issn | 2050-750X | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/10880 | - |
dc.description.abstract | CD133(+) cells in glioblastoma multiforme (GBM) display glioma stem cell (GSC) properties and have been considered to be the culprit in tumor recurrence, justifying the exploration of potential therapeutic modalities targeting CD133(+) cells. Such strategies require a drug-delivery vehicle, and increasingly, the unique properties of PEGylated liposomes are being exploited for this purpose. More advanced liposomal delivery studies have suggested conjugation of CD133 antibodies as a suitable method for targeting GSCs. For targeting studies, GSCs separated from U87 GBM cells using a magnetic bead separation method were challenged with liposomes encapsulating gemcitabine (GEM) conjugated with a CD133 monoclonal antibody (PEG-lipo-CD133-GEM). An in vitro study showed that conjugation of CD133 antibody significantly enhanced the cytotoxicity of GEM through endocytosis of CD133 surface markers overexpressed on GSCs. The anti-tumor effect of PEG-lipo-CD133-GEM was 15 times higher than that of free GEM, presumably reflecting the specific targeting of the CD133 surface marker by PEG-lipo-CD133-GEM and the enhanced stability and cytotoxicity through the PEGylated liposome formulation in xenograft models. Moreover, monitoring of body weight changes showed that the use of PEGylated liposomes significantly reduced the toxicity of GEM. Taken together, our studies demonstrate that PEG-lipo-CD133-GEM shows promise for the treatment of gliomas in vitro and in xenograft models. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ROYAL SOC CHEMISTRY | - |
dc.title | CD133 antibody-conjugated immunoliposomes encapsulating gemcitabine for targeting glioblastoma stem cells | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1039/c4tb00185k | - |
dc.identifier.scopusid | 2-s2.0-84901642255 | - |
dc.identifier.wosid | 000336853400006 | - |
dc.identifier.bibliographicCitation | JOURNAL OF MATERIALS CHEMISTRY B, v.2, no.24, pp 3771 - 3781 | - |
dc.citation.title | JOURNAL OF MATERIALS CHEMISTRY B | - |
dc.citation.volume | 2 | - |
dc.citation.number | 24 | - |
dc.citation.startPage | 3771 | - |
dc.citation.endPage | 3781 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | NEWLY-DIAGNOSED GLIOBLASTOMA | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | LIPOSOMES | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | RADIATION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MODEL | - |
dc.identifier.url | https://pubs.rsc.org/en/content/articlelanding/2014/TB/c4tb00185k#!divAbstract | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.